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ABSTRACT
Background: Novel coronavirus pneumonia (COVID-19) is prevalent around the world. We aimed to describe
epidemiological features and clinical course in Shanghai.
Methods:We retrospectively analysed 325 cases admitted at Shanghai Public Health Clinical Center, between January 20
and February 29, 2020.
Results: 47.4% (154/325) had visited Wuhan within 2 weeks of illness onset. 57.2% occurred in 67 clusters; 40% were
situated within 53 family clusters. 83.7% developed fever during the disease course. Median times from onset to first
medical care, hospitalization and negative detection of nucleic acid by nasopharyngeal swab were 1, 4 and 8 days.
Patients with mild disease using glucocorticoid tended to have longer viral shedding in blood and feces. At admission,
69.8% presented with lymphopenia and 38.8% had elevated D-dimers. Pneumonia was identified in 97.5% (314/322)
of cases by chest CT scan. Severe-critical patients were 8% with a median time from onset to critical disease of 10.5
days. Half required oxygen therapy and 7.1% high-flow nasal oxygen. The case fatality rate was 0.92% with median
time from onset to death of 16 days.
Conclusion: COVID-19 cases in Shanghai were imported. Rapid identification, and effective control measures helped to
contain the outbreak and prevent community transmission.
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Introduction
The novel coronavirus SARS-CoV-2 was not known to
infect humans until very recently [1]. It was declared a
global public health emergency of international con-
cern on January 30 and a pandemic on March 11,
2020, the first to be caused by a coronavirus [2,3].
COVID-19 is an emerging infectious disease that has
exerted a tremendous impact on public health and
socioeconomic development. Confirmed cases have
been reported in 196 countries, areas or territories
[4]. As of March 25, 2020, 375,498 cases including
16,362 deaths were reported worldwide [4]. The first
case was reported in Shanghai on January 20, 2020.
By February 29, of 337 cases confirmed in Shanghai,
287 were discharged and 3 died. While COVID-19
cases in Shanghai have all been imported, we are
not aware of a comprehensive analysis of the epidemio-
logical and clinical course of primarily imported
COVID-19 in a major urban centre. The Shanghai
Public Health Clinical Center (SPHCC) is the only
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COVID-19 designated hospital for adult patients in
Shanghai. We investigated epidemiological and clinical
features, disease severity, diagnosis, treatment, clinical
outcomes, and follow-up of COVID-19 in Shanghai,
with the hope of assisting other large urban centres
in planning for the high risk of extensive SARS-CoV-
2 transmission. The effective management of this epi-




COVID-19 confirmed patients admitted in the Emer-
gency Response Department of SPHCC January 20-
February 29 were included. Epidemiological history,
clinical manifestations, laboratory test results, and ima-
ging test results were retrospectively collected from
medical records. The study was approved by SPHCC
Ethics Committee.
Diagnosis and admission process
Individuals typically presented at Shanghai’s district
hospitals (including SPHCC). Real-time reverse tran-
scriptase polymerase chain reaction (RT–PCR) assay
for confirming SARS-CoV-2 infection were conducted
in local Centres for Disease Control and Prevention
(CDC) according to WHO protocols [5]. Patients
with positive nucleic acid test results were transferred
to SPHCC for further treatment using negative
pressure ambulances.
Follow-up after discharge
Patients were followed-up at 2- and 4-weeks post-dis-
charge to ascertain if any contacts had respiratory
symptoms or fever. Blood counts, liver and kidney
function, and nucleic acid tests were completed on
oro- or nasopharyngeal swabs or in sputum. Chest
computed tomography (CT) was provided as needed.
Related definitions
Diagnoses of COVID-19 were carried out according to
national guidelines [6]. Severe cases were defined as
dyspnoea, respiratory frequency ≥30/min, blood oxy-
gen saturation ≤93%, partial pressure of arterial oxy-
gen to fraction of inspired oxygen ratio <300 mmHg,
and/or lung infiltrates >50% within 24–48 h. Critical
cases were defined as having respiratory failure, septic
shock, and/or multiple organ dysfunction or failure.
Clinical outcomes, including continued hospitaliz-
ation, discharge and death, were recorded as of Febru-
ary 29, 2020.
Statistical analysis and plotting
Measurement data were expressed as mean ± standard
deviation or median with interquartile range. Enumer-
ation data were expressed as percentages and rates.
T-tests and non-parametric tests were used to compare
continuous data. Chi-square tests were used to com-
pare counts. The level of significance was set at 0.05.
SPSS 20.0 was used to analyse the data. All figures
were created with Microsoft PowerPoint 2016.
Results
Epidemiological features
Drawing from all 16 districts of Shanghai (Figure 1),
325 confirmed COVID-19 cases were admitted to the
Emergency Response Department of SPHCC, January
20-February 29 (Figure 2). Cases peaked January 29-
February 5, with half (52%) admitted during this
period. Median age was 51 years (range, 15–88; IQR,
36–64), 20% (65/325) were over 65 years old, and
52% (168/325) were male (Figure S1 in supplementary
material). More than half of cases (57.2%; 186/325)
were residents in other provinces. In the 14 days
prior to disease onset, almost half (47.4%; 154/325)
had visited Wuhan (the capital city of Hubei province,
800 kilometres west of Shanghai), while just over a
third (35.4%; 115/325) reported contact with a
confirmed case (Table 1). Of 67 cluster events involving
186 (57.2%) cases, 53 (79%) were family clusters com-
prising 40.3% (131/325) of all cases, 3 were colleague-
clustered events, and 3 were family-colleague mixed
clustered events (Table 1). Typical cluster event fea-
tures are shown in Figure 3.
Clinical manifestations
Among all cases, 77.2% (251/325) had fever at illness
onset, 16.0% (52/325) had fever ever during hospitaliz-
ation, and 6.8% (22/325) never developed fever. Fever
occurred in 83.7% (272/325) of hospitalized cases.
Cough at onset was reported by 28.9% (94/325) of
cases. Underlying co-morbidities were present in
28.9% (94/325) of cases, included hypertension
(15.6%; 51/325), diabetes (7.1%; 23/325), and coronary
heart disease (3.4%; 11/325). Twenty patients (6.2%)
had hepatitis B surface antigens (HBsAg), three had
hepatitis C antibodies, and one was co-infected with
human immunodeficiency virus.
Median interval times from illness onset to: first
medical care was 1 d (IQR, 0–3 days); to admission
was 4 days (IQR, 2–7.5 days); to confirmed diagnosis
was 4 days (IQR, 2–7 days); to positive nucleic acid
result was 4 days (IQR, 2–7 days). Median interval
from first medical care to positive nucleic acid result
was 2 days (IQR, 1–4 days).
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At admission, over two-thirds (69.8%; 227/325)
presented with lymphopenia; 67.1% (218/325) with
an elevated blood glucose level. Over half (56.5%;
182/322) had increased C-reactive protein (CRP);
38.8% (126/325) had elevated D-dimers; a quarter
had leukocytopenia (25.2%; 82/325) or raised procal-
citonin (PCT) (25.6%; 84/325); and 17.2% (56/325)
had hypokalemia. Patients with CD4+ T-lymphocyte
count <200/mm3 and <500/mm3 accounted for
10.2% (33/325) and 58.8% (191/325) of cases, respect-
ively (Table 2). In chest CT scans, most (97.5%; 314/
322) revealed typical pneumonia and ground-glass
opacification (93.5%, 301/322), and less than half
(42.9%, 138/322) had bilateral lung involvement.
Pleural thickening was found in 64.9% (209/322) of
scans.
Figure 1. The geographic distribution of Shanghai residents admitted to Shanghai Public Health Clinical Center. YP: Yangpu District;
HK: Hongkou District; JA: Jing’an District; HP: Huangpu District; PT: Putuo District; CN: Changning District; XH: Xuhui District. Num-
bers indicate the total cases occurred in the corresponding district. Residents from other cities are not included.
Figure 2. Daily distribution of confirmed cases of COVID-19 in Shanghai Public Health Clinical Center from January 20 to February
29, 2020.
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The proportion of mild, severe, and critical disease
was 92.0% (299/325), 3.1% (10/325), and 4.9% (16/
325), respectively. The median time from onset to
severe and critical illness was 8 and 10.5 days, respect-
ively (Figure 4).
Clinical treatment and outcomes
Half of admitted patients (50.2%; 163/325) required
oxygen during the disease course with 7.1% (23/325)
needing high-flow nasal oxygen (HFNO). Mechanical
ventilation was required by 7.1% (23/325) with extra-
corporeal membrane oxygenation (ECMO) and con-
tinuous renal replacement therapy (CRRT) each
given to 2.2% (7/325). Median time from illness onset
to oxygen therapy, HFNO, CRRT and ECMO were 7,
9, 16, and 18 days, respectively (Figure 4). Before
admission, 16.3% (53/325) had used oseltamivir, with
3 continuing the drug after admission. Only one
patient was coinfected with influenza B virus.
Antiviral therapies were prescribed to 93.2% (303/
325) of patients, with treatment consisting of at least
one of α-interferon, lopinavir/ritonavir, and/or arbidol.
Other prescribed medications included antibiotics
(38.2%; 124/325), thymosin (46.2%; 150/325), anticoa-
gulant drugs i.e. low molecular weight heparin or
heparin (22.8%; 74/325), albumin (22.8%; 74/325), glu-
cocorticoid i.e. methylprednisolone sodium succinate
(15.4%; 50/325), and vasoactive drugs (5.2%; 17/325).
Among mild cases, 22/299 (74%) did not receive anti-
viral therapy. Very few patients (1.8%; 6/325) were
given convalescent plasma therapy.
Among those treated with antivirals, median times
from illness onset to negative viral detection by phar-
yngeal swab, urine, faeces, and blood samples were 8,
8, 10, and 14 days, respectively. Median time from ill-
ness onset to negative viral detection was longer in
severe and critical patients compared with mild
patients (Table 3). Median times from initiation of
antiviral therapies to negative viral detection in phar-
yngeal swab, urine, faeces, and blood samples were 2,
2, 4, and 9 days, respectively, which were longer in
severe and critical patients compared with mild
patients (Table 3). Among 22 mild patients without
antiviral treatment, median times from illness onset
to negative viral detection in nasopharyngeal swab,
urine, faeces, and blood samples were 9, 7, 10, and
9.5 days, respectively. There were no differences
between patients with or without antiviral treatment
in time from disease onset to viral conversion (swab,
p = 0.512; urine, p = 0.832; faeces, p = 0.401; and
blood, p = 0.057). When limiting the comparison to
mild cases only, there was no evidence for any differ-
ences across sample types (Table S1 in supplementary
material). However, longer duration of viral shedding
was detected in patients prescribed with glucocorticoid,
especially in blood and faeces (Table S2 in supplemen-
tary material). Longer duration of viral shedding was
detected in blood and faeces in patients with mild dis-
ease using glucocorticoid (Table S3 in supplementary
material); however, no differences in duration of viral
shedding were observed in patients with severe-critical
disease (Table S4 in supplementary material).
The first discharge was on January 27; 85.8% of
patients were discharged within 34 days with a median
hospitalization stay of 15 days (range, 6–25 days; IQR,
6–25 days). Time from disease onset to discharge was
20 days (Table 4). There were 43 (13.2%) patients
who remained under care in our hospital, one in severe
and 11 in critical condition. Three deaths, all caused by
acute respiratory distress syndrome (ARDS) or mul-
tiple organ dysfunction (MODS), yielded a case fatality
rate of 0.92% (3/325) with median time from onset to
death of 16 days (Table 4). Case fatality rate in patients
with glucocorticoid therapy was 12%, while no patient
died among those without glucocorticoid (Table S2).
Some patients suffered from secondary infections.
Bloodstream infections appeared in 23.5% (4/17) of
patients with severe-critical illness, caused by
Table 1. Epidemiologic characteristics of 325 patients with






Age ≤17 years— no. (%) 3 (0.92)
18 years≤ Age ≤40 years— no. (%) 116 (35.7)
41years≤ Age ≤65 years— no. (%) 141 (43.4)
Age≥66 years— no. (%) 65 (20.0)
Male sex— no. (%) 168 (51.7)
Occupational classification— no. (%)
Retired personnel 130 (40)
Cadre staff 111 (34.2)
Workers 42 (12.3)




Type of residence — no. (%)
Shanghai 139 (42.8)
Other provinces except Shanghai 186 (57.23)
History of visiting within 14 days before the onset of illness





Outside Wuhan in Hubei 24/325 (7.4)
Provinces other than Hubei 27/325 (8.3)
Cluster case — no./total no. (%) 186/325
(57.2)
Family clusters (53) 131/325
(40.3)
Colleague clusters (3) 7/325 (2.2)
Family-colleague mixing clusters (3) 21/325 (6.5)
Other clusters (8) 27/325 (8.3)
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Staphylococcus haemolyticus (n = 4), Candida albicans
(n = 1), and Cryptococcus neoformans (n = 1). Half (9/
17) in severe-critical condition had positive urine cul-
ture. All the 17 patients with severe-critical illness
were offered with glucocorticoid. Positive rates in
severe-critical cases for sputum culture, throat swab
culture and stool culture were 100% (22/22), 100%
(18/18) and 85.7% (6/7), respectively.
Clinical follow-up
As of February 29, 2020, of 188 patients actively fol-
lowed up one week after discharge, 31 (16.5%) reported
mild discomfort and none reported fever. Mild discom-
fort included cough (n = 19), chest tightness (n = 4),
shortness of breath (n = 5), night sweats (n = 5), and
gastrointestinal discomfort (n = 3). Of 112 patients
who attended follow-up two weeks post-discharge,
there were no reported fevers, but 6 (5.4%) complained
of cough and chest tightness. No patients required hos-
pitalization at follow-up.
Discussion
This report details the epidemiological and clinical fea-
tures of COVID-19, including 325 RT–PCR confirmed
cases transferred to SPHCC from all districts of Shang-
hai. The findings are consistent with a typical imported
outbreak. Nearly half of cases had travelled to Wuhan
prior to disease onset, compared with 31.3% nationally
[7]. Consistent with previous studies, nearly 60% of
cases were located in clusters, with two-thirds of
these (40% of all cases) situated in families, implying
a considerable role for household transmission [8–
10]. Since effective treatment is lacking, personal pre-
ventive measures, including case isolation within
households and household quarantine, were exceed-
ingly important for prevention of onward viral
transmission.
Most confirmed cases were reported between late
January and early February 2020, with the epidemic
gradually declining by the end of February. Before
the Wuhan lockdown, the SPHCC had received its
first confirmed COVID-19 patient. Distribution of
the daily admission frequency was consistent with the
timing of the Spring Festival holiday and accompany-
ing large scale domestic population movement. Control
measures taken in most provinces during the holiday
and prior to return travel coincided with the accelera-
tion of the Wuhan outbreak and subsequent lockdown
Figure 3. Pathogen exposures and clinical courses in a clustered event.
Table 2. Laboratory results of 325 patients with COVID-19 in
Shanghai, China.
Variable Value-no./total no. (%)
Leukocyte (per mm3) <4,000 82/325 (25.2)
Lymphocyte (per mm3) <1500 227/325 (69.9)
Platelet (103 per mm3) <100 12/325 (3.7)
Alanine aminotransferase (U/liter) > 40 53/325 (16.3)
Aspartate aminotransferase (U/liter) > 40 54/325 (16.6)
Creatinine(µmol/liter) > 133 0/325 (0)
Creatine kinase (U/liter) > 200 47/325 (14.46)
Serum lactate dehydrogenase(U/liter) > 250 125/325 (38.5)
Troponin I (ng/ml) > 0.04 80/325 (24.6)
B-type natriuretic peptide precursor(pg/ml) > 250 22/325 (6.8)
Myoglobin (ng/ml) > 48.8 28/325(8.6)
Potassium (mmol/liter) < 3.5 56/325(17.2)
Sodium (mmol/liter) < 135 29/325(8.9)
Glucose (mmol/liter) > 6.1 218/325(67.1)
C-reactive protein (mg/liter) > 10 182/322(56.5)
Procalcitonin(ng/ml) > 0.05 84/325(25.9)
β-glucan (pg/ml) > 60 5/13(38.5)
CD4+T lymphocyte count<200/mm3 33/325(10.2)
CD4+T lymphocyte count<500/mm3 191/325(58.8)
Fibrinogen (g/liter) > 4.0 195/325(0.6)
Fibrin degradation product (µg/ml) > 5.0 16/325(4.9)
D-dimer (µg/ml) > 0.5 126/325(38.8)
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on January 24th. Clinical data indicating that patients
presented relatively early in their disease course,
suggested that this relatively closed epidemiological
system helped prevent additional case importation,
while aggressive control measures appear to have inter-
rupted the establishment of urban community
transmission.
Although most cases presented with fever, 7% never
developed fever throughout their illness. Fever was an
important clue for detecting imported cases. Significant
reduction of lymphopenia and CD4+T lymphopenia as
well as ground-glass lesions on CT images appeared in
most patients at admission, supporting the three clinical
criteria i.e. fever/respiratory symptoms, leukopenia and/
or lymphopenia, and typical pulmonary imaging findings,
for diagnosis of suspected COVID-19 [6]. We also found
that CT imaging helped classify disease severity as a larger
proportion of scans from critically ill patients revealed
bilateral lung involvement compared with mild cases.
Data fromprevious studies indicatinga superior sensitivity
of RT-PCR in the early infection phase (0–2 days) com-
pared with chest CT (97% vs 44%) demonstrated the
importance of ensuring an adequate supply of RT-PCR
services in outbreak control [11].
Abnormally elevated D-dimer levels were found in
over one-third patients. Zhong et al. reported that the
proportion of patients with D-dimer over 0.5 µg/ml
were significantly higher in severe cases and those
who met a composite endpoint i.e. admission to an
intensive care unit, the use of mechanical ventilation,
or death, compared with mild cases [7]. A study by
Cao et al. revealed increased odds of hospital-death
associated with D-dimer concentration over 1 µg/ml
at admission [12]. These findings may reflect the
underlying imbalance of the coagulation system trig-
gered by infection, which warrants continued study.
Although most patients in this study presented with
mild symptoms (92%), half needed oxygen therapies at
least once throughout the disease course. This result
was similar to other studies from Hubei province
[13,14]. For example, a study in Wuhan found that a
higher proportion of non-survivors received HFNO
therapy, mechanical ventilation and ECMO with
19.5%, 5.2% and 0%, surviving after receiving these
treatments, respectively [12]. In our study, the corre-
sponding proportion of all cases who received these
therapies were 7%, 7% and 2%, which was indicative
of the relatively strong pathogenicity of SARS-CoV-2.
In chest CTs, the most typical character was ground-
glass opacity observed in either or both lungs. Consist-
ent with limited host immunity and failure to constrain
the initial infection, most infiltrations appeared in the
peripheral field with pleural thickening observed in
65%. Due to the general lack of specific immunity to
this emerging pathogen, we observed each patient clo-
sely, and offered individualized treatment and support.
Although specific anti-SARS-CoV-2 drugs are cur-
rently unavailable, most of our patients received gen-
eral antiviral agents on the first day of
hospitalization. Median time to viral conversion from
initiation of antiviral treatments (or admission) using
pharyngeal swab, urine, faeces, and blood were 2, 2,
4, and 9 days, respectively. From disease onset to
viral conversion, the median duration was 8, 8, 10,
and 14 days, respectively. In contrast, the median
onset-conversion duration for pharyngeal swab was
Figure 4. Time distribution of clinical events in COVID-19 cases admitted to Shanghai Public Health Clinical Center. Numbers under-
neath indicate the number of patients who went through the corresponding events. CRRT: continuous renal replacement therapy;
ECOM: Extra-corporeal membrane oxygenation
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20 days in Wuhan, and the shortest time was 8 days
[12]. It was unclear if general antiviral agents have a
role to play in shortening the conversion duration, in
part due to a shorter median onset-admission interval
in Shanghai compared withWuhan (4 days vs 11 days).
Our data indicated that the median onset-conversion
duration was longer in patients with severe-critical dis-
ease. There was no evidence for any benefits from anti-
viral treatment in terms of viral shedding when
comparing mild patients using antivirals (n = 277)
with those that did not (n = 22), suggesting that these
drugs were not effective in shortening the infectious
period. Longer viral shedding duration was detected
in patients undergoing glucocorticoid therapy, indicat-
ing that glucocorticoid should be used with caution in
COVID-19 patients. According to Chinese national
guidelines [6] and WHO guidance [15], the routine
use of systemic corticosteroids for the treatment of
COVID-19 is not currently recommended. In our
case series, longer duration of viral shedding was
detected in blood and faeces in patients with mild dis-
ease who were using glucocorticoid. However, when
limiting analyses to patients with severe-critical illness,
no differences were observed according to glucocorti-
coid use. Dexamethasone has recently shown promise
for reducing deaths among patients who required res-
piratory support [16]. At the time of writing, these
data were yet to be peer-reviewed. Additional trials
may be necessary to assess the impact of treatment
with glucocorticoid.
Lymphopenia was the most common laboratory
abnormality at admission, occurring in nearly 70% of
cases. In Wuhan, the proportion with lymphopenia
was unevenly distributed between severe and non-
severe patients (96.1% versus 80.4%, Pearson Chi-
Square = 22.069, p < 0.001) [7]. We found a lower pro-
portion of cases presenting with lymphopenia in
Shanghai compared with non-severe cases in Wuhan,
(69.9% versus 80.4%, Pearson Chi-Square value =
14.301, p < 0.001). In addition to the shorter median
onset-admission interval, this finding supported the
idea that symptomatic patients received treatment ear-
lier in Shanghai. Temporal distribution of lymphocyte
counts throughout the disease course should be further
studied to arrive at a more convincing answer. Lym-
phocyte counts less than 800/mm3 were found to be
a strong predictor for death caused by viral pneumonia
in the MuLBSTA score model [17]. Whether this
model or lymphocyte counts can be used as a detection
tool for early disease progression is unclear. Some
patients were given thymosin to elicit an increase in
lymphocytes, but the effect on prognosis requires
further investigation. Consistent with earlier results,
this study found that inflammatory markers, such as
CRP, were elevated [7,17,18]. D-dimer elevation was
also an important feature of the disease, seen in over
one-third of cases. About a quarter of our patients
were offered anticoagulant drugs. For patients with
severe and critical conditions, positive culture results
for blood and urine samples were common, indicating
that concurrent infections may have adverse effects and
preventive antibiotics may be beneficial in some
patients as the disease progresses.
Previous reports found that the mean time of onset-
admission interval in deceased patients was 6.2 days
[18]. Data from 72,314 cases recorded by the Chinese
Center for Disease Control and Prevention indicated
an interval of 7 days between onset peak and diagnosis
peak [19,20]. Data showing that the median time from
onset to admission and diagnosis was 4 days suggested
that the identification and treatment of cases, including
isolation referrals, as observed in this relatively short
time, suggested that prompt management after illness










Time from onset to negative nucleic acid detection in pharyngeal swab—days 8 (5–12) 8 (5–11) 16 (8–22.5) <0.001
Time from onset to negative nucleic acid detection in blood—days 14 (10–18) 13 (10–17) 22.5 (16.5–30) <0.001
Time from onset to negative nucleic acid detection in urine—days 8 (5–11) 7 (5–10) 12 (7–21) <0.001
Time from onset to negative nucleic acid detection in faeces—days 10 (7–15) 10 (7–13) 21 (16.8–29) <0.001
Time from antiviral therapy to negative nucleic acid detection in pharyngeal swab—days 2 (1–6) 2 (1–6) 11 (3.8–15.5) <0.001
Time from antiviral therapy to negative nucleic acid detection in blood—days 9 (5–12) 9 (2–11) 19 (13.8–24) <0.001
Time from antiviral therapy to negative nucleic acid detection in urine—days 2 (1–4) 1 (1–4) 6 (2–14.5) <0.001
Time from antiviral therapy to negative nucleic acid detection in faeces—days 4 (2–10) 4 (1–8) 15.5 (11.5–20.8) <0.001
Values are presented by median (interquartile range). Median values of mild and severe-critical cases are compared with Mann–Whitney U test.
Table 4. Clinical course of 325 patients with COVID-19 in
Shanghai, China.
Variable Value
Time from onset to first medical care—day 1 (0–3)
Time from onset to positive nucleic acid detection in
pharyngeal swab —days
4 (2–7)
Time from first medical care to positive nucleic acid
detection in pharyngeal swab —days
2 (1–4)
Time from onset to hospitalization—days 4 (2–7.5)
Time from onset to antiviral treatment—days 4 (3–7)
Time from onset to severe illness—days 8 (4–10)
Time from onset to critical illness—days 10.5 (5.3–12.5)
Time from onset to oxygen therapy—days 7 (4–9)
Time from onset to HFNO—day 9 (6–11)
Time from onset to ECMO—days 18 (10–33)
Time from onset to CRRT—days 16 (6–18)
Time from onset to death—days 16 ± 13.7*
Time from onset to discharge—days 20 (16–25)
Values are presented by median (interquartile range). *Mean value. HFNO:
High-flow nasal oxygen. ECMO: Extracorporeal membrane oxygenation.
CRRT: Continuous renal replacement therapy.
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onset helped to blunt onward community trans-
mission. In China, it was recommended that patients
with mild disease also receive inpatient isolation and
treatment.
Disease severity requiring oxygen, HFNO or mech-
anical ventilation typically emerged one week after
onset. Multiple organ dysfunction required composite
treatments and often occurred 2 weeks after disease
onset. Hospitalization lasted 2 weeks, with 3 weeks
being the typical period from onset to discharge.
Therefore, 1–2 weeks after disease onset was critical
period for diagnosis and treatment.
The case-fatality rate was lower (0.92%) than same
day national data (3.6%) [21], and consistent with a
previously reported comparison of the concurrent
national case fatality rate of 3.57% and 0.85% outside
Wuhan [22]. Studies have suggested that old age and
comorbidities are risk factors for death [12,23]. In
our cohort, 20% of patients were over 65 years old,
nearly 30% had underlying disease. Case fatality rate
in patients with and without glucocorticoid in the full
case series was 12% and 0, respectively. As deaths
only occurred in the severe-critical group, this com-
parison was inadequate to draw inferences on the
impact of glucocorticoid use. The main cause of
death was ARDS and MODS. The average hospital
stay in Shanghai was 15 days was slightly longer than
national average [7]. Risk factors for severe-critical dis-
ease and death will be examined in subsequent
analyses.
In aggressive follow-up, there were no reported
fevers or hospitalizations. With no human-to-human-
transmission observed, COVID-19 patients had fully
recovered two weeks after discharge.
We did not observe cases among children and preg-
nant women, which was consistent with studies show-
ing a typically mild disease course among children and
a lack of evidence for higher risks in pregnancy. More-
over, our research may not reflect the transmission and
clinical features completely since undetected asympto-
matic and mild cases may exist. Other limitations
included small numbers of severe and critically ill
patients for study and potential lack of representative-
ness of imported cases if extrapolated to urban com-
munity transmission.
Conclusions
This retrospective study of 325 cases of COVID-19 in
Shanghai found that the epidemic was imported and
transmitted within clusters. The disease typically pre-
sented as a viral pneumonia involving both lungs,
with half of cases requiring oxygen therapy. Time
from onset to admission and the high proportion of
mild illness suggested patients presented early in
their disease course. The timing of Spring Festival in
relation to the Wuhan lockdown helped to limit case
importation, facilitate early presentation and manage-
ment of symptomatic patients, and prevent onward
community transmission. Moving forward, we hope
to continue to deliver early and optimal care, limit
community transmission, and tying the case fatality
to the lower end of the known range.
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